College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Department of Dermatology, University of Cincinnati, Cincinnati, OH, USA.
J Dermatolog Treat. 2022 Feb;33(1):143-145. doi: 10.1080/09546634.2020.1729951. Epub 2020 Feb 20.
The systemic drug choices for psoriasis have been increasing due to a greater understanding of the pathophysiology of the disease. In this setting of increasing drug availability, it is unknown how the use of different agents in psoriasis is changing. This study examines changes in prescribing trends for systemic therapy in patients with psoriasis.
We analyzed the United States National Ambulatory Medical Care Survey data from 2007 to 2016 for visits in which psoriasis was the primary diagnosis and patients were treated with approved systemic medications. Weighting factors were used to provide nationally representative estimates.
We found 20 (19, 21) million office visits during the 10-year study period. There was found to be no significant difference in the use of systemic agents by age ( = .3), race () or sex ( = .2). The use of systemic agents ( = .002) and biologic agents ( = .003) had increased over time. There was no significant trend over time for the use of methotrexate ( = .5) or oral small molecule inhibitors ( = .3).
This study suggests that in the United States the use of biologic and systemic agents overall has increased. The use of methotrexate and oral small molecule inhibitors overall has not changed.
由于对疾病病理生理学有了更深入的了解，治疗银屑病的系统药物选择也越来越多。在药物可及性不断增加的情况下，尚不清楚银屑病中不同药物的使用情况正在发生怎样的变化。本研究调查了银屑病患者系统治疗药物处方趋势的变化。
我们分析了 2007 年至 2016 年美国全国门诊医疗调查数据，这些患者的主要诊断为银屑病，接受了批准的系统药物治疗。采用加权因素提供全国代表性估计。
在 10 年的研究期间，我们发现有 2000 万（1900 万，2100 万）次门诊就诊。年龄（ = .3）、种族（）或性别（ = .2）对系统药物的使用无显著差异。系统药物（ = .002）和生物制剂（ = .003）的使用随时间推移而增加。甲氨蝶呤（ = .5）或口服小分子抑制剂（ = .3）的使用随时间推移无明显趋势。
本研究表明，在美国，整体上生物制剂和系统药物的使用有所增加。甲氨蝶呤和口服小分子抑制剂的总体使用并未改变。
